Shire PLC (NASDAQ:SHPG) was the target of a large decrease in short interest in January. As of January 31st, there was short interest totalling 2,421,141 shares, a decrease of 34.8% from the January 12th total of 3,712,240 shares. Currently, 0.8% of the company’s stock are sold short. Based on an average daily trading volume, of 1,775,924 shares, the days-to-cover ratio is presently 1.4 days.

SHPG has been the topic of a number of recent research reports. Zacks Investment Research raised Shire from a “sell” rating to a “hold” rating in a research report on Friday, October 27th. Royal Bank of Canada reissued a “buy” rating on shares of Shire in a research report on Thursday, November 16th. Cantor Fitzgerald set a $222.00 price target on Shire and gave the stock a “buy” rating in a research report on Thursday, November 16th. Cowen set a $225.00 price target on Shire and gave the stock a “buy” rating in a research report on Sunday, October 29th. Finally, Bank of America increased their price target on Shire from $236.00 to $237.00 and gave the stock a “buy” rating in a research report on Monday, February 5th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $212.50.

A number of hedge funds have recently modified their holdings of the stock. Commerzbank Aktiengesellschaft FI boosted its position in Shire by 22.1% during the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 2,073 shares of the biopharmaceutical company’s stock valued at $322,000 after purchasing an additional 375 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its position in Shire by 6.2% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 6,492 shares of the biopharmaceutical company’s stock valued at $1,073,000 after purchasing an additional 381 shares in the last quarter. Pitcairn Co. boosted its position in Shire by 26.5% during the third quarter. Pitcairn Co. now owns 1,917 shares of the biopharmaceutical company’s stock valued at $293,000 after purchasing an additional 401 shares in the last quarter. ETRADE Capital Management LLC boosted its position in Shire by 6.9% during the fourth quarter. ETRADE Capital Management LLC now owns 7,212 shares of the biopharmaceutical company’s stock valued at $1,119,000 after purchasing an additional 466 shares in the last quarter. Finally, Thompson Investment Management Inc. boosted its position in Shire by 5.2% during the third quarter. Thompson Investment Management Inc. now owns 9,390 shares of the biopharmaceutical company’s stock valued at $1,438,000 after purchasing an additional 468 shares in the last quarter. 20.74% of the stock is currently owned by institutional investors.

Shares of Shire (NASDAQ SHPG) traded up $0.19 during mid-day trading on Wednesday, reaching $132.86. The company had a trading volume of 2,040,000 shares, compared to its average volume of 1,510,000. Shire has a 12 month low of $123.73 and a 12 month high of $192.15. The company has a market capitalization of $40,100.00, a P/E ratio of 25.02, a P/E/G ratio of 0.71 and a beta of 1.41. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.52 and a current ratio of 0.98.

Shire (NASDAQ:SHPG) last issued its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported $3.98 earnings per share for the quarter, beating analysts’ consensus estimates of $3.86 by $0.12. Shire had a return on equity of 14.41% and a net margin of 10.95%. The company had revenue of $4.15 billion for the quarter. During the same period in the previous year, the business earned $3.37 EPS. Shire’s revenue for the quarter was up 8.9% compared to the same quarter last year. sell-side analysts predict that Shire will post 15 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This news story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2018/02/14/shire-plc-shpg-sees-large-drop-in-short-interest.html.

About Shire

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.